Re: American Association for Cancer Research 2019

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: American Association for Cancer Research 2019

in response to

American Association for Cancer Research 2019

frohlir944

posted on Mar 29, 2019 09:05PM

"Meeting today till April 1st, last presentation mentions first compani to present joint BETi results. Anybody know more, what day, is this joint with Pfizer?"

Slide 14 of BIO-Europe: "Clinical data to be presented at American Association for Cancer Research 2019. Zenith will be the first to release clinical combination data with a BETi at a major scientific meeting." That AACR presentation is coming up on April 1. It's the enzalutamide combo for mCRPC. Not the pending PARP inhibitor trial with Pfizer for TNBC.